Credit Suisse Reiterates Outperform Rating on Prometheus Biosciences Inc (RXDX)

December 7, 2022 8:45 AM EST Send to a Friend
Credit Suisse analyst Martin Auster reiterated an Outperform rating and $59.00 price target on Prometheus Biosciences Inc (NASDAQ: RXDX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login